Los Angeles Capital Management LLC Sells 60,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Los Angeles Capital Management LLC reduced its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 31.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 134,467 shares of the biopharmaceutical company’s stock after selling 60,515 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $3,093,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Huntington National Bank boosted its position in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the period. Xponance Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 3.1% in the third quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 406 shares during the period. Arizona State Retirement System boosted its position in shares of Ultragenyx Pharmaceutical by 2.2% in the third quarter. Arizona State Retirement System now owns 25,176 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 533 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of Ultragenyx Pharmaceutical by 2.0% in the third quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock worth $817,000 after purchasing an additional 534 shares during the period. Finally, Van ECK Associates Corp boosted its position in shares of Ultragenyx Pharmaceutical by 26.1% in the third quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 549 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 4,683 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70. Following the completion of the transaction, the chief financial officer owned 110,342 shares in the company, valued at $2,747,515.80. This trade represents a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Shehnaaz Suliman sold 5,740 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $25.12, for a total transaction of $144,188.80. Following the transaction, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. This trade represents a 17.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 20,103 shares of company stock valued at $478,186 in the last quarter. 5.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $22.79 on Wednesday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The firm has a fifty day moving average price of $23.79 and a 200 day moving average price of $25.27. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -3.73 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter last year, the business earned ($1.57) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% compared to the same quarter last year. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.57 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. Cantor Fitzgerald upped their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, May 21st. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Finally, Barclays dropped their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $59.56.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.